Organon inks $103M deal for per­tuzum­ab and deno­sum­ab biosim­i­lars

Organon is look­ing to boost its biosim­i­lar port­fo­lio with two well-known brand copies in de­vel­op­ment by Shang­hai-based Hen­lius Biotech.

The women’s health phar­ma is pay­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER